Assessing Prognosis: Factors Influencing Outcomes in Hospitalized Lung Cancer DOI Creative Commons
J. Peña, L. Gutierrez-Sainz, Diego Jiménez-Bou

et al.

Onco, Journal Year: 2024, Volume and Issue: 4(4), P. 458 - 470

Published: Dec. 19, 2024

Background: Patients with lung cancer experience higher rates of hospitalization due to their elevated mortality and associated comorbidities. Hospital admissions among oncology patients often indicate organ vulnerability are linked poor prognosis. This study aimed assess the characteristics potential prognostic factors hospitalized patients. Methods: We retrospectively analyzed 646 admitted from June 2021 May 2022 Medical Oncology Service at La Paz University (Madrid, Spain). Results: During this period, 158 had (24.5%). The median overall survival since admission (mOSSA) was 3.3 months (95%CI: 1.86–7.74). In univariate analysis, poorer mOSSA for tumor-related causes (1.33 vs. 7.30 months, p < 0.001), ECOG ≥ 2 (2.43 8.50 NLR 6 (1.87 7.40 months), PNI ≤ 40 (1.67 4.97 LDH 210 (2.27 7.87 = 0.044). multivariate independent included (p 0.032, aHR 1.81, 95%CI: 1.05–3.11) 0.041, 1.80, 1.03–3.16). Conclusions: is a event, particularly when or decline in performance status.

Language: Английский

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3 DOI
Natasha B. Leighl, Nofisat Ismaila, Greg Andrew Durm

et al.

Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. updated on a regular schedule by standing expert panel systematically reviews the health literature continuous basis, as described ASCO Guidelines Methodology Manual . follow Conflict of Interest Policy Implementation Clinical Practice and updates not intended to substitute independent professional judgment treating clinician do account individual variation among patients. See appendix disclaimers other important information ( Appendix 1 2 ). Updates published regularly can be found at https://ascopubs.org/nsclc-non-da-living-guideline

Language: Английский

Citations

0
Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma DOI
Masahiro Torasawa, Tatsuya Yoshida, Kouya Shiraishi

et al.

Lung Cancer, Journal Year: 2025, Volume and Issue: 202, P. 108494 - 108494

Published: March 12, 2025

Language: Английский

Citations

0
Precision Oncology in Non-small Cell Lung Cancer: A Comparative Study of Contextualized ChatGPT Models DOI Open Access

Ethan Brown,

Harshal A. Shah, Brianna M. Donnelly

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

Objectives: The growing adoption of Large Language Models (LLMs) in medicine has raised important questions about their potential utility for clinical decision support within oncology. This study aimed to evaluate the effects various contextualization methods on ChatGPT's ability provide National Comprehensive Cancer Network (NCCN) guideline-aligned recommendations managing non-small cell lung cancer (NSCLC). Methodology: GPT-4o, base GPT-4, and GPT-4 models contextualized with prompts PDF documents were asked identify preferred chemotherapies twelve advanced cancers given molecular profiles derived from 2024 NCCN Clinical Practice Guidelines Oncology NSCLC. GPT responses subsequently compared guidelines using readability scores qualitative reviewer assessments (1) recommendation specific targeted therapy, (2) agreement NCCN-guideline-preferred therapies, (3) guideline non-concordant (4) provision supplementary information. Results: PDF+Prompt model demonstrated elevated 23/24 versus 17/24 (P = 0.040) 18/24 GPT-4o 0.089). No contained therapies contrast 4/12 GPT4 0.093) 5/12 GPT4o 0.037). Comparison response between or showed a lower mean word count (both P < 0.001), Simple Measure Gobbledygook (SMOG) score Gunning Fog 0.001 0.002 GPT-4o). Prompting alone did not significantly improve reduce rate therapy recommendations. Conclusions: performance gains observed following suggest that broader applications LLMs oncology may exist than current literature indicates. provides proof concept use showcases accessibility. Future studies validating this application additional types real-life patient encounters could an bridge eventual adoption.

Language: Английский

Citations

0
Recent advances in therapeutic strategies for non-small cell lung cancer DOI Creative Commons
Po‐Lan Su, Naoki Furuya,

Atif Asrar

et al.

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: March 27, 2025

The development of targeted therapy with small-molecule tyrosine kinase inhibitors and immunotherapy immune checkpoints has ushered in the era precision medicine treating lung cancer, which remains leading cause cancer-related deaths worldwide. Both have significantly improved survival patients metastatic non-small-cell cancer (NSCLC). Additionally, recent groundbreaking studies demonstrated their efficacy both perioperative setting following concurrent chemoradiotherapy early-stage NSCLC. Despite significant advancements first-line treatment options, disease progression inevitable for most advanced NSCLC, necessitating exploration optimization subsequent therapeutic strategies. Emerging novel agents are expanding options beyond. Recently, emerging bispecific antibodies shown enhanced efficacy. For instance, amivantamab been approved as a epidermal growth factor receptor (EGFR)-mutant including those EGFR exon 20 insertion mutations. antibody–drug conjugates (ADCs), HER2-targeting trastuzumab deruxtecan, TROP2-targeting ADCs, HER3-targeting patritumab MET-targeting telisotuzumab vedotin, promising outcomes several clinical trials. This review summarizes challenges associated evolving NSCLC landscape.

Language: Английский

Citations

0
Plasma-First Testing in Advanced Lung Cancer: Evidence and Implications DOI
Kaushal Parikh, Ayisha Hashmi, Pradeep S. Chauhan

et al.

Journal of Thoracic Oncology, Journal Year: 2025, Volume and Issue: 20(4), P. 411 - 414

Published: April 1, 2025

Language: Английский

Citations

0
Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications DOI Open Access

Nyein Wint Yee Theik,

Suset Almuinas de armas,

Daniel Rosas

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3802 - 3802

Published: April 17, 2025

Non-small cell lung cancer (NSCLC) is operated commonly by diverse genetic alterations, and oncogenic fusions represent a significant therapeutic role. Common include ALK, ROS1, RET, NTRK, signaling pathways in tumorigenesis. Recent advances investigating tumor molecular biology underlying fusions, including chromosomal rearrangements, highlighting their role as drivers. The development of targeted therapies, such tyrosine kinase inhibitors (TKIs), has impacted most patients’ NSCLC treatment. Despite the greater profiles, remarkable efficiency tolerable side effects compared to traditional chemotherapy, challenges, acquired mutations, lead more ongoing research-optimized future therapies.

Language: Английский

Citations

0
Functions of CAFs in microenvironment of non-small cell lung cancer: based on updated hallmarks of cancer DOI Creative Commons
Xiaoyan Feng,

Binghan Zhu,

Yali Peng

et al.

ONCOLOGIE, Journal Year: 2024, Volume and Issue: 26(5), P. 701 - 709

Published: Sept. 1, 2024

Abstract Non-small cell lung cancer (NSCLC) is the most common subtype of cancer, which ranks as first malignant tumor in mortality. The occurrence and development NSCLC are closely related to microenvironment (TME). Cancer-associated fibroblasts (CAFs) considered be critical regulators NSCLC, have essential effects on multiple biological characteristics NSCLC. hallmarks biology been updated recently, however, there no reviews revisiting function CAFs microenvironment. This article origin, markers, classification CAFs, their impacts potential therapeutic targets help develop individualized treatment plans for

Language: Английский

Citations

2
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer DOI
Rudolf M. Huber, Diego Kauffmann‐Guerrero

Current Opinion in Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 4, 2024

Immune checkpoint inhibitors (ICIs) and targeted therapies have changed the landscape of management nonsmall cell lung cancer (NSCLC) dramatically. Whereas ICIs in NSCLC without specific driver mutations are well established it is unclear what place mutation-positive is. This review summarizes current view on use NSCLC.

Language: Английский

Citations

1
Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta DOI Creative Commons
Winson Y. Cheung, Chantelle Carbonell, Vishal Navani

et al.

Current Oncology, Journal Year: 2024, Volume and Issue: 31(8), P. 4382 - 4396

Published: July 31, 2024

There is limited information on the treatment trajectory and outcomes of patients with advanced cEGFRm NSCLC treated osimertinib in routine clinical practice Canada. By using analyzing population-based administrative data detailed chart abstraction province Alberta, our objective was to capture Canadian-specific real-world patterns, health outcomes, healthcare resource utilization (HCRU) who were (a) (b) those receiving after osimertinib. In study cohort, we found that overall survival rates for less favorable than observed trials (24.0 versus 38.6 months). The attrition rate substantial high HCRU persisted across many years diagnosis treatment. This provides important evidence contemporary survival, use among suggests further research efforts are needed improve therapeutic options both first subsequent line settings.

Language: Английский

Citations

0
Clinical Interest in Exome-Based Analysis of Somatic Mutational Signatures for Non-Small Cell Lung Cancer DOI Open Access

Morgane Peroz,

Hugo Mananet,

Nicolas Roussot

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 3115 - 3115

Published: Sept. 9, 2024

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality. This study investigates clinical interest whole exome sequencing (WES) for analyzing somatic mutational signatures in patients with advanced or metastatic NSCLC treated current standard care.

Language: Английский

Citations

0